Wednesday 12/17 Insider Buying Report: SRRK, ADGM

Scholar Rock director Srinivas Akkaraju bought $1.18M of SRRK (29,599 shares at $39.92) on Friday; the stock traded as high as $45.32 during the session (about a 13.5% move from the purchase) and was roughly up 0.4% on Wednesday. The purchase follows Akkaraju’s prior roughly $18.8M accumulation at about $37.58 per share over the past year, indicating continued insider buying. Separately, Adagio Medical CEO Todd Usen bought $225,973 of stock (207,315 shares at $1.09) while Adagio shares were down about 2.5% on Wednesday. These transactions signal management confidence and may draw investor attention, though short-term price action has diverged between the two names.

Analysis

Scholar Rock director Srinivas Akkaraju purchased $1.18 million of SRRK on Friday, acquiring 29,599 shares at $39.92 per share while the stock traded intraday as high as $45.32, about a 13.5% premium to the purchase price. The note records SRRK trading up roughly 0.4% on Wednesday, indicating the insider buy coincided with positive intraday momentum.

The article also states Akkaraju made a prior transaction in the past twelve months “purchasing $18.81M shares for a cost of $37.58 a piece,” which, taken together with the new purchase, signals continued insider accumulation. The provided per-ticker sentiment for SRRK is positive (0.6) and overall sentiment is mildly positive (0.3), but market impact is scored low (0.25), implying limited immediate market-moving power from these trades.

Separately, Adagio Medical CEO Todd Usen bought $225,973 of ADGM, acquiring 207,315 shares at $1.09 while ADGM traded down about 2.5% on Wednesday. That transaction is smaller in dollar terms and the per-ticker sentiment for ADGM is only mildly positive (0.1), suggesting a more cautious interpretation of conviction compared with the Scholar Rock activity.

Insider purchases in both names are meaningful as signals of management confidence, but the article and signals together imply these are incremental catalysts rather than definitive valuation-changing events; investors should therefore watch for follow-on filings, sustained price performance, and trading volume to validate a durable trend.

Key Decisions for Investors

• Consider initiating or modestly increasing SRRK exposure on controlled pullbacks given repeated insider accumulation and recent intraday strength, but size positions conservatively relative to risk tolerance
• Monitor for additional insider filings and sustained price/volume follow-through at or above recent buy levels ($39.92 and the prior $37.58 reference) before materially adding to SRRK positions
• Treat ADGM CEO buying as a limited conviction signal given the modest dollar amount and the stock’s ~2.5% intraday decline; wait for confirmatory insider activity or clearer positive price action before increasing exposure
• Employ defined position sizing or hedges because market-impact signals are low and insider buying alone does not guarantee a durable fundamental turnaround